How to Buy Calliditas Therapeutics Ab Stock
Calliditas Therapeutics Ab
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases.
Calliditas Therapeutics Ab stock last closed at $19.45, up 5.14% from the previous day, and has decreased 23.3% in one year. It has overperformed other stocks in the Biotechnology industry by 0 percentage points. Calliditas Therapeutics Ab stock is currently +27.54% from its 52-week low of $15.25, and -33.62% from its 52-week high of $29.30.
As of Apr 25, 2024, there are 59.58M shares of CALT outstanding. The market capitalization of CALT is $579.42M. In the past 24 hours, 5994 CALT shares were traded.
How to Buy Calliditas Therapeutics Ab Stock
Not sure how to invest in Calliditas Therapeutics Ab stock? Here's how.
- Choose where to buy Calliditas Therapeutics Ab stock: You need to pick a stock brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you choose where to buy Calliditas Therapeutics Ab stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Deposit funds into your investment account: Choose your payment method and add your information.
- Analyze Calliditas Therapeutics Ab stock: The Calliditas Therapeutics Ab ticker symbol is CALT. Is Calliditas Therapeutics Ab stock a good investment? Should you buy shares of CALT? How do CALT's underlying business fundamentals look? Do top analysts think Calliditas Therapeutics Ab is a good buy? Why has CALT's stock price moved recently? (Hint: Our stock research website can help you figure out if CALT is a good stock to buy).
- Place your CALT trade: Decide if you will purchase CALT shares at the current market price or use a limit order to purchase CALT shares at a particular price.
- Get notifications regarding your CALT investment: Create a watchlist to the latest updates on your new investment in Calliditas Therapeutics Ab stock.
Step 1: Choose where to buy Calliditas Therapeutics Ab stock
You will need an online brokerage account to access the NASDAQ market and buy CALT shares.
Our recommended brokerage: eToro
We believe that eToro is the best place to buy stocks. Here's why:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to global financial markets: From Tech to Healthcare, New York to London — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro boasts a community with more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by signing up for an account with eToro today.
Open eToro AccountStep 2: Open a brokerage account
Now that you've selected the best brokerage, it's time to fill out some personal information so you are able to buy CALT stock today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to open a new trading account.
- Submit your details by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have opened your account on the best stock trading app, you can securely and quickly fund your account:
Watch the video below to see the process of depositing funds into your new investment account.
Step 4: Analyze Calliditas Therapeutics Ab stock
After you have selected the best place to buy Calliditas Therapeutics Ab stock, it's critical to analyze their stock before you invest, so you actually wrap your head around the risk and upside.
Calliditas Therapeutics Ab shares data
Calliditas Therapeutics Ab Zen Score
WallStreetZen was designed to help part-time investors perform more accurate fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on CALT's stock page.
Is CALT stock overvalued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge CALT's fair value.
Using relative valuations methods:
- CALT may be overvalued based on its P/B ratio of 18.83x, relative to Biotechnology industry P/B ratio of 5.8x
You can access additional valuation analysis on CALT's stock here.
CALT Financial Health Overview
Pros:
- CALT has cash burn of 41125275. It has sufficient cash and short-term investments to cover this for at least one year.
- CALT has $89.50M in cash and short term investments. This is sufficient to cover its annual cash burn of $41.13M.
- There are more short-term assets than long-term liabilities on the CALT balance sheet.
- There are more short-term assets than short-term liabilities on the CALT balance sheet.
Cons:
- CALT has a relatively high debt to equity ratio of 4.55.
- CALT profit margin has gone up by 0.13 percentage points in the past year, but the company is still unprofitable.
- Total CALT debt is higher than 5 years ago, relative to shareholder equity.
Do analysts think it's a good time to buy Calliditas Therapeutics Ab stock
Out of 1 Wall Street analysts who monitor CALT, the consensus analyst rating on CALT is a Buy
Please note that analyst ratings are not recommendations, nor are they financial advice.
You can dive deeper into what analysts are forecasting on the Calliditas Therapeutics Ab stock forecast page.
Metrics for Advanced CALT Traders
CALT Growth Metrics
Last year, CALT revenue was $110.93M. During the last 4 year, CALT's revenue has increased by 56.67% per year. This was faster than the Biotechnology industry average of 28.62%.
Dive into CALT's earnings and revenue performance here.
What are CALT insiders up to?
Over the last year, insiders at CALT have not bought or sold any shares.
Dig into more about who owns CALT stock here.
Does CALT stock generate passive income?
No, Calliditas Therapeutics Ab doesn't provide an income stream by paying out dividends.
What others are saying about CALT
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Place your CALT trade
There are two main types of orders:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are generally the best for newer investors. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at an exact dollar amount, place a limit order.
Press the Open Trade button and your broker will execute your order.
If you require more help with buying stocks on eToro, watch the how to video below:
Step 6: Get notifications regarding your CALT investment
Now that you own some shares in CALT, you'll want to keep up with your stock purchase.
Start a watchlist to track the most important metrics related to your CALT stock.
CALT Feed
How to Buy Stock in Calliditas Therapeutics Ab
To summarize, here are the 6 steps to buy Calliditas Therapeutics Ab stock:
- Choose where to buy Calliditas Therapeutics Ab stock
- Open a brokerage account
- Deposit funds into your investment account
- Analyze Calliditas Therapeutics Ab stock
- Place your CALT trade
- Get notifications regarding your CALT investment
If you are looking for a place to buy stocks, eToro is our favorite venue.
Get Started with eToro TodayIf you want to get notifications regarding your new investment in Calliditas Therapeutics Ab, create a watchlist today.
Trending Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.